JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Krishnamurthy, S.
Right arrow Articles by Krishnamurthy, G. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Krishnamurthy, S.
Right arrow Articles by Krishnamurthy, G. T.
Journal of Nuclear Medicine Vol. 44 No. 4 499-504
© 2003 by Society of Nuclear Medicine

Clinical Investigations

Comparison of Gallbladder Function Obtained with Regular CCK-8 and Pharmacy-Compounded CCK-8

Shakuntala Krishnamurthy, MD, Jeri Cerulli-Switzer, Nicholas Chapman, BS and Gerbail T. Krishnamurthy, MD

1 Tuality Community Hospital/Tuality Healthcare, Hillsboro, Oregon

This study was undertaken to test whether the octapeptide of cholecystokinin (regular CCK-8) and pharmacy-compounded CCK-8 produce similar results with regard to gallbladder function. Methods: Twenty patients with suspected gallbladder disease were enrolled into quantitative cholescintigraphy. Each patient was infused for10 min with 3 ng/kg/min of regular CCK-8 and pharmacy-compounded CCK-8, sequentially, with a 30-min interval between the beginning of infusion. The gallbladder ejection fraction, latent period, ejection period, and ejection rate were measured with both agents. Results: Both regular CCK-8 and pharmacy-compounded CCK-8 produce similar, but not identical, results with close correlation between them with reference to all of the measured functions of the gallbladder. There is neither potentiation nor inhibition of the first dose on the effects of the second dose of CCK-8. Conclusion: Pharmacy-compounded CCK-8 functions much similar to that of regular CCK-8 as long as an interval of at least 30 min is allowed between doses.

Key Words: pharmacy-compounded octapeptide of cholecystokinin • sincalide • gallbladder ejection fraction • chronic cholecystitis




This article has been cited by other articles:


Home page
 JNMHome page
T. B. Bartel, M. E. Juweid, J. A. Ponto, and M. M. Graham
Corn Oil Emulsion: A Simple Cholecystagogue for Diagnosis of Chronic Acalculous Cholecystitis
J. Nucl. Med., January 1, 2005; 46(1): 67 - 74.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
G. T. Krishnamurthy, S. Krishnamurthy, and P. H. Brown
Constancy and Variability of Gallbladder Ejection Fraction: Impact on Diagnosis and Therapy
J. Nucl. Med., November 1, 2004; 45(11): 1872 - 1877.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
D. T Guarasci, L. H. N Trinh, G. R Baeumler, and E. M Bednarczyk
Compounded Versus Proprietary Sincalide for Evaluation of Gallbladder Ejection Fraction
Ann. Pharmacother., March 1, 2004; 38(3): 428 - 432.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
C. C. Chen, G. T. Campbell, G. T. Krishnamurthy, P. H. Brown, M. P. Jacobs, and C. D. Peterson
Measurement of Gallbladder Ejection Fraction
J. Nucl. Med., September 1, 2003; 44(9): 1544 - 1546.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2003 by the Society of Nuclear Medicine.